Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine Hydrochloride, the active ingredient in Mydriasert, is a mydriatic agent presented as a sterile ophthalmic solution for ocular use. It, together with Tropicamide, produces rapid pupil dilation to facilitate diagnostic eye examinations in adults and children, and is used by ophthalmologists for routine fundus evaluation and pre‑operative assessment.

GNH USA supplies Mydriasert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets.

Mydriasert, a combination mydriatic ophthalmic solution, is used to induce pupil dilation for diagnostic eye examinations.

- Diagnostic eye examinations: provides sufficient mydriasis for fundus photography, retinal imaging, and slit‑lamp evaluation. - Pre‑operative ocular assessment: facilitates intra‑ocular pressure measurement and surgical planning. - Glaucoma screening: allows thorough visualization of the optic nerve head.

Mydriasert may cause ocular and systemic adverse reactions, most of which are mild and transient.

Common Side Effects: - Transient ocular burning or stinging: mild discomfort upon instillation. - Conjunctival hyperemia: redness of the eye. - Temporary blurred vision: due to enlarged pupil. - Increased intra‑ocular pressure: especially in susceptible patients.

Serious or Rare Side Effects: - Acute angle‑closure glaucoma: sudden severe eye pain and vision loss. - Systemic hypertension: elevated blood pressure after absorption. - Allergic reaction: swelling, itching, or rash around the eye.

Before using Mydriasert, consider the following precautions to minimize risk.

- Assess intra‑ocular pressure: avoid use in patients with uncontrolled glaucoma. - Screen for cardiovascular disease: phenylephrine may raise systemic blood pressure. - Avoid in patients with hypersensitivity: discontinue if allergic signs appear. - Use with caution in children: pediatric response may differ. - Limit repeated dosing: excessive dilation can increase pressure. - Store at room temperature: keep in original container, protect from light and moisture.

Mydriasert can interact with other medications; be aware of the following.

Major Interactions (Avoid): - Systemic sympathomimetics (e.g., pseudoephedrine): may cause additive hypertension. - Monoamine oxidase inhibitors: increased risk of hypertensive crisis. - Topical beta‑blockers: may reduce mydriatic effect.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs (e.g., atropine): may enhance pupil dilation. - Oral antihypertensives: monitor blood pressure if systemic absorption occurs.